Lin Chuanyan, Yuan Liyong, Shi Jun, Kong Lingsi, Luo Ni, Wang Jianlin
Department of Anesthesiology, Ningbo Sixth Hospital, Ningbo City, Zhejiang Province, 315140, People's Republic of China.
Ther Clin Risk Manag. 2025 May 23;21:747-755. doi: 10.2147/TCRM.S515869. eCollection 2025.
Esketamine and dexmedetomidine are commonly used sedatives in surgery, which can result in minimal respiratory depression and analgesic activity. This study investigated the sedative effect of esketamine combined with dexmedetomidine on patients undergoing spinal tumor (ST) surgery.
We did a retrospective analysis at the Anesthesiology Department of Ningbo City's the sixth Hospital. They studied 75 ST surgery patients who got esketamine in combination with dexmedetomidine (Group ED) between April 2022 and June 2024. In a 1:1 cohort, compare these individuals to those who only received dexmedetomidine at the same time period (Group D). The primary outcome is perioperative hemodynamic status. The secondary outcomes were pain intensity, intraoperative neurophysiological monitoring (IONM), and the occurrence of adverse responses.
Compared with group E, the group ED had lower mean arterial pressure (MAP), heart rate (HR), and visual-analogue scale (VAS) scores after the start of surgery (all P<0.05). There was no significant difference in the waiting time for perioperative motor evoked potential (MEP) and the intensity of the first induced MEP current between the two groups (all P>0.05); The Group ED first induced MEP amplitude, somatosensory evoked potential (SEP) amplitude, and MEP amplitude greater than the Group D, while SEP latency and MEP latency were smaller than the Group D (all P<0.05). There was no significant difference in the incidence of perioperative adverse events between the two groups (P>0.05).
Compared with dexmedetomidine alone, the combination of esketamine and dexmedetomidine during ST surgery can demonstrated superior sedation and pain control without increasing adverse event risk, making it a viable alternative for ST surgery anesthesia.
艾司氯胺酮和右美托咪定是手术中常用的镇静剂,可导致最小程度的呼吸抑制和镇痛活性。本研究调查了艾司氯胺酮联合右美托咪定对脊柱肿瘤(ST)手术患者的镇静效果。
我们在宁波市第六医院麻醉科进行了一项回顾性分析。他们研究了2022年4月至2024年6月期间接受艾司氯胺酮联合右美托咪定治疗的75例ST手术患者(ED组)。在1:1队列中,将这些患者与同期仅接受右美托咪定治疗的患者(D组)进行比较。主要结局是围手术期血流动力学状态。次要结局包括疼痛强度、术中神经生理监测(IONM)和不良反应的发生情况。
与E组相比,ED组在手术开始后平均动脉压(MAP)、心率(HR)和视觉模拟量表(VAS)评分更低(均P<0.05)。两组围手术期运动诱发电位(MEP)等待时间和首次诱发MEP电流强度无显著差异(均P>0.05);ED组首次诱发MEP波幅、体感诱发电位(SEP)波幅大于D组,而SEP潜伏期和MEP潜伏期小于D组(均P<0.05)。两组围手术期不良事件发生率无显著差异(P>0.05)。
与单独使用右美托咪定相比,ST手术期间艾司氯胺酮与右美托咪定联合使用可表现出更好的镇静和疼痛控制效果,且不增加不良事件风险,使其成为ST手术麻醉的可行替代方案。